Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by Grenadier66on Dec 04, 2010 3:32am

660 Views

Post# 17800273

No Insider Trading

I find it comforting that no insider trading occurred during the current rollercoaster ride (source: https://www.canadianinsider.com/coReport/allTransactions.php?ticker=RVX):

Resverlogix Corp. (RVX)						As of December 3rd, 2010
Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	# or value acquired or disposed of	Unit Price
Oct 13/10	Oct 07/10	Zuerblis, Kenneth	Direct Ownership	Options	50 - Grant of options	150,000
Oct 07/10	Sep 29/10	Zuerblis, Kenneth	Direct Ownership	Options	00 - Opening Balance-Initial SEDI Report
Oct 07/10	Sep 29/10	Zuerblis, Kenneth	Direct Ownership	Common Shares	00 - Opening Balance-Initial SEDI Report
Aug 11/10	Aug 05/10	Cochrane, William Arthur	Direct Ownership	Common Shares	10 - Acquisition in the public market	3,000	$2.650
Aug 06/10	Aug 06/10	Mccaffrey, Donald J.	Direct Ownership	Options	50 - Grant of options	100,000
Aug 06/10	Aug 03/10	Mccaffrey, Donald J.	Direct Ownership	Common Shares	47 - Disposition by gift	-75,000	$2.800
Jun 28/10	Jun 28/10	Wagner, Gregory Steven	Direct Ownership	Options	52 - Expiration of options	-100,000
Jun 08/10	Jun 08/10	McNeill, Kelly Bret	Direct Ownership	Options	52 - Expiration of options	-75,000
May 25/10	May 21/10	Mccaffrey, Donald J.	Direct Ownership	Common Shares	10 - Acquisition in the public market	2,000	$3.650
May 25/10	May 21/10	Mccaffrey, Donald J.	Direct Ownership	Common Shares	10 - Acquisition in the public market	1,000	$3.800